Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

DOI Web Site Web Site 23 Citations

Journal

Citations (23)*help

See more

Report a problem

Back to top